000168745 001__ 168745
000168745 005__ 20260218132343.0
000168745 0247_ $$2doi$$a10.1016/S0002-8703(99)70262-0
000168745 0248_ $$2sideral$$a232
000168745 037__ $$aART-1999-232
000168745 041__ $$aeng
000168745 100__ $$0(orcid)0000-0001-7043-0952$$aCiveira, F.$$uUniversidad de Zaragoza
000168745 245__ $$aComparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia
000168745 260__ $$c1999
000168745 5060_ $$aAccess copy available to the general public$$fUnrestricted
000168745 5203_ $$aBackground Type III hyperlipoproteinemia is characterized by the accumulation of chylomicron and very low density lipoprotein (VLDL) remnants. Individuals with this disorder have a high risk of premature atherosclerosis, and hypolipidemic drugs are useful in their management. Methods We compared, in a double-blind, placebo-controlled, randomized crossed study, the effects of gemfibrozil (1200 mg/day) and simvastatin (20 mg/day) on lipids, apolipoprotein AI, apolipoprotein B, and apolipoprotein E and on lipids and apolipoprotein B content in VLDL, intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) in 10 patients with type III hyperlipoproteinemia. Results Levels of total cholesterol, VLDL cholesterol, IDL cholesterol, and apolipoprotein B decreased with both drugs. Larger reductions in triglycerides (109 ± 28.2 mg/dL, P = .005), VLDL cholesterol (24.7 ± 10.9 mg/dL, P = .05), and VLDL triglycerides (86.3 ± 20.2 mg/dL, P = .003) were obtained with gemfibrozil compared with simvastatin. LDL cholesterol reduction was more effective with simvastatin than with gemfibrozil (44.3 ± 17.1 mg/dL, P = .03). HDL cholesterol after gemfibrozil was 5.71 ± 2.37 mg/dL higher than after simvastatin. Conclusions In patients with type III hyperlipoproteinemia gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs. (Am Heart J 1999;138:156-62.)
000168745 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
000168745 590__ $$a2.021$$b1999
000168745 591__ $$aCARDIAC & CARDIOVASCULAR SYSTEMS$$b16 / 64 = 0.25$$c1999$$dQ1$$eT1
000168745 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000168745 700__ $$aCenarro, A.
000168745 700__ $$aFerrando, J.
000168745 700__ $$0(orcid)0000-0002-1309-4363$$aPuzo, J.$$uUniversidad de Zaragoza
000168745 700__ $$0(orcid)0000-0002-5123-2480$$aGarcia-Otin, A. L.
000168745 700__ $$0(orcid)0000-0001-5956-4319$$aMozas, P.
000168745 700__ $$0(orcid)0000-0001-8807-9187$$aPocovi, M.$$uUniversidad de Zaragoza
000168745 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina y Psiquiatr.$$cArea Medicina
000168745 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000168745 773__ $$g138, 1 (1999), 156-162$$pAm. heart j.$$tAMERICAN HEART JOURNAL$$x0002-8703
000168745 8564_ $$s345445$$uhttps://zaguan.unizar.es/record/168745/files/texto_completo.pdf$$yPostprint
000168745 8564_ $$s3119597$$uhttps://zaguan.unizar.es/record/168745/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000168745 909CO $$ooai:zaguan.unizar.es:168745$$particulos$$pdriver
000168745 951__ $$a2026-02-18-12:27:34
000168745 980__ $$aARTICLE